Collaboration brings Children’s Tumor Foundation’s deep NF1 expertise and patient and family perspectives into development of ...
Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated ...
Climb Bio, Inc. (Nasdaq: CLYM, “Climb Bio”) and Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), today announced additional ...
(Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® ...
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups ...
Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to ...
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen ...
HLX79/E-602 plus rituximab produced faster responses and a higher response rate than rituximab alone, with a safety profile ...
Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to ...
As both Taysha Gene Therapies and Neurogene warm up for an important year of readouts, the Rett syndrome community is pinning ...
Each inducement RSU award shall vest as follows, subject to continuing service: one-sixth of the shares subject to the ...
UCB, a global biopharmaceutical company focused on severe diseases, today announced the establishment of the Emmanuel Janssen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results